W STRATEGIES, LLC for CALIFORNIA LIFE SCIENCES
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
March 2016 CMS proposed rule implementing a new Part B drug payment model. H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Health Issues HCR
Promoted life sciences community and communicated economic and health benefits of the industry. S.1878: Advancing Hope Act of 2016 - "To extend the pediatric priority review voucher program". H.R. 34: 21st Century Cures Act conference report, specifically with respect to reforms at NIH and S. 1878: Advancing Hope Act of 2016 - "To extend the pediatric priority review voucher program". Education about the value of innovative new medicines. Education about FDA performance on review of drugs and medical devices. H.R. 3299: Strengthening Public Health Emergency Response Act of 2015.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.